<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HER2 positive colorectal cancer &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/her2-positive-colorectal-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Fri, 12 Jun 2026 11:17:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>HER2 positive colorectal cancer &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head &#038; neck, sarcoma) or HER2-mutant non-small cell lung cancer</title>
		<link>https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 13:07:57 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/</guid>

					<description><![CDATA[This clinical trial focuses on treating patients with various types of solid tumors that have specific characteristics related to the HER2 gene. The study includes several types of cancer: endometrial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, and sarcoma. These cancers must either show high levels of HER2 protein or have [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial focuses on treating patients with various types of <b>solid tumors</b> that have specific characteristics related to the <b>HER2 gene</b>. The study includes several types of cancer: <b>endometrial cancer</b>, <b>colorectal cancer</b>, <b>head and neck cancer</b>, <b>non-small cell lung cancer</b>, and <b>sarcoma</b>. These cancers must either show high levels of HER2 protein or have mutations in the HER2 gene.</p>
<p>The study uses a medication called <b>zanidatamab</b> (also known as <b>JZP598</b>), which is given through an <b>intravenous</b> infusion. This medicine is a powder that is first made into a concentrated solution before being given to patients. The maximum daily dose that can be given is 2400 milligrams, and treatment may continue for up to three years.</p>
<p>The main goal of this research is to determine how well zanidatamab works in treating these different types of cancer. The study will look at whether tumors respond to the treatment by shrinking or disappearing. Doctors will monitor patients regularly using scans to check how the tumors are responding to the treatment and to watch for any side effects that may occur.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
